Fulcrum Historical Balance Sheet

FULC Stock

USD 3.44 0.19 5.85%

Trend analysis of Fulcrum Therapeutics balance sheet accounts such as Other Current Liabilities of 4.5 M or Total Current Liabilities of 15 M provides information on Fulcrum Therapeutics' total assets, liabilities, and equity, which is the actual value of Fulcrum Therapeutics to its prevalent stockholders. By breaking down trends over time using Fulcrum Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Fulcrum Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Fulcrum Therapeutics is a good buy for the upcoming year.

Fulcrum Therapeutics Inventory

(728,460)

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.

About Fulcrum Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Fulcrum Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Fulcrum Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Fulcrum Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Fulcrum currently owns. An asset can also be divided into two categories, current and non-current.

Fulcrum Therapeutics Balance Sheet Chart

At present, Fulcrum Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 16.6 M, whereas Total Assets are forecasted to decline to about 164.9 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity Short Term Debt Intangible Assets

Add Fundamental

Total Assets

Total assets refers to the total amount of Fulcrum Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Fulcrum Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Fulcrum Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Fulcrum Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.

Most accounts from Fulcrum Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Fulcrum Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.At present, Fulcrum Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 16.6 M, whereas Total Assets are forecasted to decline to about 164.9 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	74K	6.9M	6.5M	4.5M
Total Assets	235M	226.7M	257.7M	164.9M

Other Current Liab Total Assets

Fulcrum Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.62	0.81	1.0	0.26	0.93	0.27	-0.42	-0.93	0.81	0.54	0.87	-0.02	0.9	1.0	0.81	0.95	0.92	0.83	0.93	-0.52	0.9	0.99	0.87	1.0	0.7
Other Current Liab	0.62		0.74	0.59	0.36	0.66	0.46	-0.41	-0.69	0.52	0.52	0.82	-0.24	0.71	0.61	0.36	0.67	0.61	0.83	0.68	-0.45	0.34	0.68	0.82	0.61	0.53
Total Current Liabilities	0.81	0.74		0.78	0.5	0.81	0.27	-0.51	-0.74	0.93	0.59	0.84	-0.04	0.72	0.81	0.85	0.77	0.66	0.76	0.78	-0.7	0.58	0.78	0.97	0.8	0.49
Total Stockholder Equity	1.0	0.59	0.78		0.22	0.93	0.24	-0.38	-0.92	0.79	0.51	0.85	0.0	0.9	1.0	0.81	0.94	0.93	0.8	0.93	-0.5	0.92	0.99	0.83	1.0	0.71
Other Liab	0.26	0.36	0.5	0.22		0.14	0.74	-0.95	-0.04	0.28	0.88	0.39	-0.68	0.09	0.26	0.27	0.15	-0.06	0.56	0.08	0.1	-0.09	0.18	0.55	0.29	0.08
Net Tangible Assets	0.93	0.66	0.81	0.93	0.14		0.28	-0.25	-0.97	0.84	0.41	0.78	-0.04	0.92	0.94	0.78	0.96	0.87	0.76	0.99	-0.51	0.86	0.94	0.84	0.92	0.75
Property Plant And Equipment Net	0.27	0.46	0.27	0.24	0.74	0.28		-0.74	-0.19	0.09	0.75	0.32	-0.96	0.23	0.26	-0.03	0.26	0.01	0.64	0.23	0.46	0.03	0.23	0.43	0.29	0.23
Net Debt	-0.42	-0.41	-0.51	-0.38	-0.95	-0.25	-0.74		0.2	-0.29	-0.98	-0.56	0.63	-0.29	-0.41	-0.29	-0.32	-0.11	-0.71	-0.22	-0.06	-0.06	-0.33	-0.61	-0.45	-0.25
Retained Earnings	-0.93	-0.69	-0.74	-0.92	-0.04	-0.97	-0.19	0.2		-0.73	-0.38	-0.83	-0.07	-0.98	-0.92	-0.7	-0.99	-0.93	-0.77	-0.99	0.56	-0.84	-0.95	-0.8	-0.91	-0.84
Accounts Payable	0.81	0.52	0.93	0.79	0.28	0.84	0.09	-0.29	-0.73		0.37	0.68	0.1	0.65	0.81	0.91	0.74	0.67	0.59	0.78	-0.68	0.73	0.77	0.85	0.79	0.38
Cash	0.54	0.52	0.59	0.51	0.88	0.41	0.75	-0.98	-0.38	0.37		0.68	-0.59	0.47	0.53	0.35	0.49	0.26	0.82	0.4	-0.02	0.18	0.47	0.71	0.58	0.42
Non Current Assets Total	0.87	0.82	0.84	0.85	0.39	0.78	0.32	-0.56	-0.83	0.68	0.68		-0.03	0.88	0.86	0.62	0.87	0.79	0.93	0.82	-0.6	0.61	0.87	0.92	0.87	0.66
Non Currrent Assets Other	-0.02	-0.24	-0.04	0.0	-0.68	-0.04	-0.96	0.63	-0.07	0.1	-0.59	-0.03		0.05	-0.02	0.22	0.02	0.22	-0.4	0.03	-0.67	0.15	0.01	-0.18	-0.04	0.0
Other Assets	0.9	0.71	0.72	0.9	0.09	0.92	0.23	-0.29	-0.98	0.65	0.47	0.88	0.05		0.9	0.63	0.99	0.89	0.83	0.96	-0.55	0.76	0.92	0.8	0.9	0.88
Cash And Short Term Investments	1.0	0.61	0.81	1.0	0.26	0.94	0.26	-0.41	-0.92	0.81	0.53	0.86	-0.02	0.9		0.82	0.94	0.92	0.82	0.93	-0.52	0.9	0.99	0.86	1.0	0.7
Net Receivables	0.81	0.36	0.85	0.81	0.27	0.78	-0.03	-0.29	-0.7	0.91	0.35	0.62	0.22	0.63	0.82		0.72	0.71	0.49	0.74	-0.7	0.74	0.77	0.76	0.8	0.5
Common Stock Total Equity	0.95	0.67	0.77	0.94	0.15	0.96	0.26	-0.32	-0.99	0.74	0.49	0.87	0.02	0.99	0.94	0.72		0.9	0.83	0.99	-0.53	0.83	0.95	0.84	0.94	0.85
Common Stock Shares Outstanding	0.92	0.61	0.66	0.93	-0.06	0.87	0.01	-0.11	-0.93	0.67	0.26	0.79	0.22	0.89	0.92	0.71	0.9		0.68	0.9	-0.61	0.89	0.96	0.71	0.91	0.73
Non Current Liabilities Total	0.83	0.83	0.76	0.8	0.56	0.76	0.64	-0.71	-0.77	0.59	0.82	0.93	-0.4	0.83	0.82	0.49	0.83	0.68		0.78	-0.29	0.55	0.82	0.9	0.84	0.65
Capital Surpluse	0.93	0.68	0.78	0.93	0.08	0.99	0.23	-0.22	-0.99	0.78	0.4	0.82	0.03	0.96	0.93	0.74	0.99	0.9	0.78		-0.55	0.85	0.94	0.82	0.92	0.81
Inventory	-0.52	-0.45	-0.7	-0.5	0.1	-0.51	0.46	-0.06	0.56	-0.68	-0.02	-0.6	-0.67	-0.55	-0.52	-0.7	-0.53	-0.61	-0.29	-0.55		-0.42	-0.54	-0.58	-0.49	-0.37
Other Current Assets	0.9	0.34	0.58	0.92	-0.09	0.86	0.03	-0.06	-0.84	0.73	0.18	0.61	0.15	0.76	0.9	0.74	0.83	0.89	0.55	0.85	-0.42		0.9	0.6	0.88	0.54
Other Stockholder Equity	0.99	0.68	0.78	0.99	0.18	0.94	0.23	-0.33	-0.95	0.77	0.47	0.87	0.01	0.92	0.99	0.77	0.95	0.96	0.82	0.94	-0.54	0.9		0.84	0.98	0.72
Total Liab	0.87	0.82	0.97	0.83	0.55	0.84	0.43	-0.61	-0.8	0.85	0.71	0.92	-0.18	0.8	0.86	0.76	0.84	0.71	0.9	0.82	-0.58	0.6	0.84		0.86	0.58
Net Invested Capital	1.0	0.61	0.8	1.0	0.29	0.92	0.29	-0.45	-0.91	0.79	0.58	0.87	-0.04	0.9	1.0	0.8	0.94	0.91	0.84	0.92	-0.49	0.88	0.98	0.86		0.71
Property Plant And Equipment Gross	0.7	0.53	0.49	0.71	0.08	0.75	0.23	-0.25	-0.84	0.38	0.42	0.66	0.0	0.88	0.7	0.5	0.85	0.73	0.65	0.81	-0.37	0.54	0.72	0.58	0.71

Click cells to compare fundamentals

Fulcrum Therapeutics Account Relationship Matchups

Fulcrum Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	110.4M	129.6M	235M	226.7M	257.7M	164.9M
Other Current Liab	5.9M	7.7M	74K	6.9M	6.5M	4.5M
Total Current Liabilities	12.1M	26.7M	19.2M	16.7M	13.7M	15.0M
Total Stockholder Equity	87.2M	95.2M	211.5M	198.9M	235.2M	142.3M
Other Liab	11.1M	7.7M	4.3M	197K	177.3K	168.4K
Net Tangible Assets	87.2M	95.2M	211.5M	198.9M	228.8M	240.2M
Property Plant And Equipment Net	87.9M	8.4M	7.4M	16.0M	12.4M	16.6M
Net Debt	(96.7M)	(57.0M)	(35.4M)	(21.7M)	(14.7M)	(15.5M)
Retained Earnings	(150.8M)	(221.6M)	(302.5M)	(412.3M)	(509.7M)	(484.2M)
Accounts Payable	2.2M	4.1M	4.8M	3.6M	2.8M	3.2M
Cash	96.7M	57.1M	35.4M	35.1M	25.6M	36.9M
Non Current Assets Total	10.4M	16.7M	9.0M	19.2M	15.5M	13.4M
Non Currrent Assets Other	(78.7M)	7.2M	542K	2.1M	3.1M	3.3M
Other Assets	1.2M	1.7M	1.6M	3.2M	3.7M	3.9M
Cash And Short Term Investments	96.7M	112.9M	218.2M	202.9M	236.2M	147.7M
Net Receivables	111K	2.7M	4.1M	1.1M	2.2M	1.7M
Common Stock Total Equity	23K	28K	41K	52K	59.8K	62.8K
Common Stock Shares Outstanding	11.0M	25.4M	35.4M	45.0M	61.3M	32.4M
Liabilities And Stockholders Equity	110.4M	129.6M	235M	226.7M	257.7M	164.9M
Non Current Liabilities Total	11.1M	7.7M	4.3M	11.0M	8.8M	7.7M
Capital Surpluse	237.9M	316.8M	514.4M	612.0M	703.8M	739.0M
Capital Lease Obligations	46K	50K	17K	13.4M	10.8M	11.4M
Inventory	3.0M	(2.8M)	(473K)	(852K)	(766.8K)	(728.5K)
Other Current Assets	284K	74K	4.2M	3.5M	3.7M	1.9M
Other Stockholder Equity	237.9M	316.8M	514.4M	612.0M	744.9M	404.7M
Total Liab	23.3M	34.4M	23.5M	27.7M	22.5M	22.7M
Net Invested Capital	87.2M	95.2M	211.5M	198.9M	235.2M	136.8M
Property Plant And Equipment Gross	9.2M	8.4M	7.4M	6.9M	25.2M	26.4M
Total Current Assets	100.1M	112.9M	226.0M	207.5M	242.2M	151.5M
Accumulated Other Comprehensive Income	(110.4M)	(2K)	(397K)	(797K)	(136K)	(142.8K)
Non Current Liabilities Other	150K	55K	3.1M	197K	226.6K	215.2K
Net Working Capital	87.9M	92.8M	206.8M	190.8M	228.5M	137.5M
Short Term Debt	50K	17K	9.6M	5.2M	4.4M	3.0M
Common Stock	23K	28K	41K	52K	62K	35.0K
Property Plant Equipment	9.2M	8.4M	7.4M	6.9M	7.9M	8.3M
Short Long Term Debt Total	50K	17K	469K	13.4M	10.8M	11.4M
Current Deferred Revenue	4.0M	14.9M	4.7M	934K	840.6K	798.6K
Capital Stock	23K	28K	41K	52K	62K	40.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:

How To Invest In Fulcrum

Details

Is Fulcrum Stock a good investment?

Details

What is Fulcrum Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.29)

Revenue Per Share

1.317

Quarterly Revenue Growth

89.909

Return On Assets

(0.07)

Return On Equity

(0.07)

The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fulcrum Historical Balance Sheet

Fulcrum Therapeutics Inventory

(728,460)

About Fulcrum Balance Sheet Analysis

Fulcrum Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Intangible Assets

Fulcrum Therapeutics balance sheet Correlations

Fulcrum Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fulcrum Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Accumulated Amortization	Total Assets
Other Current Liab	Total Current Liabilities
Total Stockholder Equity	Other Liab
Net Tangible Assets	Property Plant And Equipment Net
Total Permanent Equity	Warrants
Noncontrolling Interest In Consolidated Entity	Net Debt
Retained Earnings	Accounts Payable
Cash	Non Current Assets Total
Non Currrent Assets Other	Other Assets
Long Term Debt	Cash And Short Term Investments
Net Receivables	Good Will
Common Stock Total Equity	Retained Earnings Total Equity
Common Stock Shares Outstanding	Short Term Investments
Long Term Debt Total	Liabilities And Stockholders Equity
Non Current Liabilities Total	Capital Surpluse
Capital Lease Obligations	Negative Goodwill
Inventory	Other Current Assets
Other Stockholder Equity	Total Liab
Additional Paid In Capital	Deferred Long Term Liab
Net Invested Capital	Preferred Stock Redeemable
Long Term Investments	Property Plant And Equipment Gross
Short Long Term Debt	Preferred Stock Total Equity
Total Current Assets	Accumulated Other Comprehensive Income
Treasury Stock	Non Current Liabilities Other
Accumulated Depreciation	Net Working Capital
Deferred Long Term Asset Charges	Short Term Debt
Intangible Assets	Common Stock
Temporary Equity Redeemable Noncontrolling Interests	Property Plant Equipment
Short Long Term Debt Total	Current Deferred Revenue
Capital Stock

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Cash And Short Term Investments

Capital Surpluse	- 0.99	Retained Earnings
Common Stock Total Equity	- 0.99	Retained Earnings
Other Assets	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.97	Net Tangible Assets
Non Currrent Assets Other	- 0.96	Property Plant And Equipment Net